This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials, Journal of Experimental & Clinical Cancer Research, May 2011, Springer Science + Business Media,
DOI: 10.1186/1756-9966-30-54.
You can read the full text:
The following have contributed to this page
